Effect of glargine insulin delivery method (Pen Device Versus Vial/Syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes

Endocrine Practice

Volumn 20, Issue 6, 2014, Pages 536-539

  Seggelke, Stacey ^a   Hawkins, R ^a   Gibbs, Joanna ^a   Rasouli, Neda ^a   Wang, Cecilia ^a   Draznin, Boris ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; LONG ACTING INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INJECTION PEN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYRINGE; TREATMENT INDICATION; AGED; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE; MIDDLE AGED; PATIENT PREFERENCE;

EID: 84903644349     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13404.OR     Document Type: Article

References (18)

1. Korytkowski M, Bell D, Jacobsen C, Suwannasari R A multicenter, randomized, open-label, comparative, twoperiod crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/ syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003.;25:2836Y2848
2. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004.;27: 2495Y2497
3. Schwartz S, Vlajnic A. Validation of the SoloSTAR insulin pen. Diabetes Technol Ther. 2008.;10:351Y357
4. Hancu N, Czupryniak L, Genestin E, Sourij H. A pan- European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type1 and type 2 diabetes. J Diabetes Sci Technol. 2011.;5:1224Y1234
5. Toscano D, Brice J, Alfaro C. Usage and perception of pen injectors for diabetes management: A survey of type 2 diabetes patients in the United States. J Diabetes Sci Technol. 2012.;6:686Y694
6. Haynes RB, McKibbob KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996.;348:383Y386
7. Schectman J, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002.;25:1015Y1021
8. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004.;27:1218Y1224
9. Aikens JE, Piette JD. Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes. Diabet Med. 2013.;30:338Y344
10. Diel AK, Bauer RL, Sugarek NJ. Correlates of medication compliance in non-insulin-dependent diabetes mellitus. South Med J. 1987.;80:332Y335
11. Chousa FP, Gullen VFG, Otero MD, Beltran DO, Lopez RP, Sanchez JM. Usefulness of six indirect methods to evaluate drug therapy compliance in non insulin dependent diabetes mellitus. Revista Clinica Espanola. 1997.; 197:555Y559
12. Peterson GM, McLean S, Senator GB. Determinants of patient compliance, control, presence of complications, and handicap in non-insulin-dependent diabetes. Aust N Z J Med. 1984.;14:135Y141
13. Cohen HW, Shmukler C, Ullman R, Rivera CM, Walker EA. Measurements of medication adherence in diabetic patients with poorly controlled HbA(1c). Diabet Med. 2010.;27:210Y216
14. Grabner M, Chu J, Raparla S, Quimbo R, Zhou S, Conoshenti J. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial. Postgrad Med. 2013.;125:204Y213
15. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011.;17:845Y852
16. Carter J, Roberts A. Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. Curr Med Res Opin. 2008.;24: 2741Y2749
17. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data. Clin Ther. 2006.;28:1701Y1725
18. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care cost and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: A retrospective database analysis. Clin Ther. 2007.;29:1294Y1305.